HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases.

Abstract
A crossover study was planned in order to compare the effects of captopril and slow channel calcium entry blocker (Ca antagonist) on urinary protein excretion in 7 hypertensive patients with renal diseases, including 4 with IgA nephropathy, 2 with lupus nephritis and 1 with benign nephrosclerosis. Captopril decreased urinary protein excretion by 52% without any change in creatinine clearance, while Ca antagonist was having a slight effect on proteinuria even though the drug showed an equivalent antihypertensive effect as captopril. These results suggest that the attenuation of proteinuria induced by captopril may be related to an inhibition of angiotensin II formation and/or a direct action of this drug on protein permeability of glomerular basement membrane.
AuthorsT Ikeda, D Nakayama, T Gomi, J Sakurai, T Yamazaki, M Yuhara
JournalNephron (Nephron) Vol. 52 Issue 1 Pg. 72-5 ( 1989) ISSN: 1660-8151 [Print] Switzerland
PMID2651951 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Calcium Channel Blockers
  • Captopril
Topics
  • Adult
  • Calcium Channel Blockers (therapeutic use)
  • Captopril (therapeutic use)
  • Clinical Trials as Topic
  • Female
  • Humans
  • Hypertension, Renal (drug therapy)
  • Male
  • Middle Aged
  • Proteinuria (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: